Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates induction therapy with carfilzomib-cyclophosphamide-dexamethasone before
salvage high-dose melphalan with autologous stem cell support (HDT) in multiple myeloma
patients with relapse after HDT done at diagnosis. In addition, the study evaluates the
effect of maintenance therapy after salvage HDT in multiple myeloma. After salvage HDT half
of the patients receive maintenance therapy with carfilzomib/dexamethasone while the other
half are observed without maintenance therapy.